Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23ec872637dd23aee3ea8f3de7258301 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06Q50-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
filingDate |
2010-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c956e0aea06c1f1f65c0bfac4cab9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca74da5b4198dbd25b636711fd6868b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d59493e603e9959d5feafc79df963848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7b4f64be51d96eccdcab0b0a895952f |
publicationDate |
2011-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2011035232-A1 |
titleOfInvention |
Methods of treating hepatic encephalopathy |
abstract |
Treatment of hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The further provided are methods for treating these subjects. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10314828-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017520624-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335397-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633384-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9265458-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980478-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020227516-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10709694-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9380976-B2 |
priorityDate |
2008-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |